Company news

Sangamo Therapeutics, Inc. news in 2025

Sangamo Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

December 17, 2025

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

December 1, 2025

Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease

November 20, 2025

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results

November 5, 2025

Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call

October 29, 2025

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

September 3, 2025

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

August 6, 2025

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

July 30, 2025

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

June 23, 2025

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

May 11, 2025

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

May 11, 2025

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

May 11, 2025

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

May 5, 2025

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

May 5, 2025

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

April 27, 2025

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

April 2, 2025

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

March 16, 2025

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference

March 5, 2025

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile

February 5, 2025

Calls in 2025

Decks in 2025